المؤلفون: S. Yu. Dobner, S. A. Tuzikov, T. S. Аgeeva, E. N. Samtsov, A. V. Dubakov, I. G. Sinilkin, A. Yu. Dobrodeev

المصدر: Сибирский онкологический журнал, Vol 19, Iss 1, Pp 111-118 (2020)

مصطلحات موضوعية: рак легкого, хроническая обструктивная болезнь легких, легочная реабилитация, длительно действующие бронхолитики, тиотропия бромид в ингаляторе – респимат, функция внешнего дыхания, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.siboncoj.ru/jour/article/view/1330Test; https://doaj.org/toc/1814-4861Test; https://doaj.org/toc/2312-3168Test

الوصول الحر: https://doaj.org/article/7d9e77835d63472982cdb4b89a46e7a7Test

المؤلفون: Zyryanov S.K., Galatonova Y.A.

المصدر: Медицинский совет

مصطلحات موضوعية: тиотропия бромид, олодатерол, фармакоэкономический анализ, tiotropium-olodaterol, Copd, Respimat, хобл, респимат

العلاقة: https://doi.org/10.21518/2079-701X-2018-6-61-65Test; https://openrepository.ru/article?id=245729Test

الإتاحة: https://doi.org/10.21518/2079-701X-2018-6-61-65Test
https://openrepository.ru/article?id=245729Test

المؤلفون: S. Zyryanov K., Y. Galatonova A., С. Зырянов К., Ю. Галатонова А.

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2018); 61-65 ; Медицинский Совет; № 6 (2018); 61-65 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-6

مصطلحات موضوعية: COPD, tiotropium-olodaterol, Respimat, ХОБЛ, тиотропия бромид, олодатерол, Респимат, фармакоэкономический анализ

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/2375/2357Test; Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease, 2017. http://goldcopd.orgTest/.; Newman SP. Inhaler treatment options in COPD. Eur Resp Rev, 2005, 14: 102–108.; Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J of COPD, 2009, 4: 381–390.; Spiolto Respimat 2.5 microgram/2.5 micro-gram, inhalation solution [summary of product characteristics]. 2016. http: //mri.medagencies. org/download/NL_H_3157_001_.; Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J of Aerosol Med, 2005 September, 18(3): 273-282.; Ram FSF, Carvallho CR, White J. Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis, 2011, 6: 129–139.; Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest, 1998, 113(4): 957–963.; Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med, 2005, 18(3): 264–272.; Calverley PM, Könen-Bergmann M, Richard F, Bell S, Hohlfeld JM. Tiotropium Respimat Versus HandiHaler: Comparison of Broncho-dilator Efficacy of Various Doses in Clinical Trials. Adv Ther, 2016 May, 33(5): 786-93.; Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J of COPD, 2007, 2(4): 559–565.; Ichinose M, Fujimoto T, Fukuchi Y. tiotropium 5microg via Respimat and 18 microg via hand-ihaler, efficacy and safety in Japanese COPD patients. Respir. Med, 2010, 104(2): 228–236.; Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis, 2016, 11: 3163-3177.; Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med, 2015, 109(10): 1312–1319.; Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther, 2015, 32: 53–59.; Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G et al. Tiotropium and olodaterol fixed dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J, 2015, 45(4): 969–979.; O’Donnell D, Casabur R, De Sousa D, Xue W, Frith P, Hamiltonet A et al. Effects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: The Moracto™ studies. Am J Respir Crit Care Med, 2015, 191: A3972.; Maltais F, Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Eur Respir J, 2014, 44(Suppl 58): 238.; Selya-Hammer C, Gonzalez-Rojas GN, Baldwin M, Ternouth A, Miravitlles M, Maureen Rutten-van Mölken M. Development of an enhanced healtheconomic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis, 2016, 10(5): 391–401.; Job FM van Boven, Kocks WHJ, Postma JM. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropi-um-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis, 2016 Sep 19, 11: 2191-2201.; Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed dose combination versusother LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res, 2016 Nov 7, 8: 667-674.; Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. UPLIFT Study Investigators. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med, 2008, 359(15): 1543–1554.; Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res, 2013, 14: 40.; https://www.med-sovet.pro/jour/article/view/2375Test

الإتاحة: https://doi.org/10.21518/2079-701X-2018-6-61-65Test
https://doi.org/10.21518/2079-701X-2018-6Test
https://www.med-sovet.pro/jour/article/view/2375Test

المؤلفون: Оболонкова, Н. И., Масленников, А. А.

مصطلحات موضوعية: медицина, пульмонология, болезни легких, хроническая обструктивная болезнь легких, легочная гипертензия, Спиолто Респимат

العلاقة: Оболонкова, Н.И. Влияние Спиолто респимат на легочную гипертензию у больных хронической обструктивной болезнью легких / Н. И. Оболонкова, А. А. Масленников // Научный результат. Сер. Медицина и фармация. - 2017. - Т.3, №2.-С. 3-8. - DOI:10.18413/2313-8955-2017-3-2-3-8. - Библиогр.: с. 7-8.; http://dspace.bsu.edu.ru/handle/123456789/42871Test

الإتاحة: https://doi.org/10.18413/2313-8955-2017-3-2-3-8Test
http://dspace.bsu.edu.ru/handle/123456789/42871Test

المؤلفون: V. V. Arkhipov, D. E. Arkhipova, N. B. Lazareva, В. В. Архипов, Д. Е. Архипова, Н. Б. Лазарева

المصدر: PULMONOLOGIYA; Том 26, № 3 (2016); 352-356 ; Пульмонология; Том 26, № 3 (2016); 352-356 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-3

مصطلحات موضوعية: Респимат, dry powder inhalers, Respimat, порошковые ингаляторы

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/727/635Test; Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.; Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328.; Pothirat C., Chaiwong W., Phetsuk N. et al. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1291–1298.; Alaboud A., Assi K.H., and Chrystyn H. In vitro characterization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012; 3: 803–806.; Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.; Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2"agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497–1504.; Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J. Allergy Clin. Immunol. 2013; 132 (1): 45–54.; Zanen P., Go L.T., Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51 (10): 977–980.; Criée C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single"dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.; Colthorpe P., Voshaarb T., Kieckbusch T. et al. Delivery characteristics of a low"resistance dry"powder inhaler used to deliver the longacting muscarinic antagonist glycopyrronium. J. Drug Ass. 2013; 2: 11–16.; Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single"dose dry"powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.; Demoly P., Hagedoorn P., de Boer A.H., Frijlink H.W. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med. 2014; 108 (8): 1195–1203.; Malmberg L.P., Rytilä P., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.; Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol. Med. 2002; 15 (3): 297–303.; Alaboud S.S. In"vitro inhalation performance for formoterol dry powder and metred dose inhalers. University of Bradford; 2011. https://bradscholars.brad.ac.uk/bitstream/handle/10454/5686/Final_Ph.DTest 12.4.2012pdf.pdf?sequence=1 Date last accessed: June 14, 2016.; Hamilton M., Leggett R., Pang C. et al. In vitro dosing performance of the ellipta dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™). J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 498–506.; Ciciliani A., Wachtel H., Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.; Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.; Corradi M., Chrystyn H., Cosio B.G. et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp. Opin. Drug Deliv. 2014; 11 (9): 1497–1506.; Scichilone N. Asthma control: the right inhaler for the right patient. Adv. Ther. 2015; 32 (4): 285–292.; Pasquali I. et al. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14–18, 2012; Chicago. Poster: M1150.; Newman S.P. Principles of metered"dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1790.; Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC"free HFA"beclomethasone metereddose inhaler compared with CFC"beclomethasone. Eur. Respir. J. 1998; 12 (6): 1346–1353.; Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol. Med. 2005; 18 (3): 273–282.; Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938.; Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18 (3): 264–272.; Ciciliani A., Wachtel H., Langguth P. Comparing Respimat Soft Mist inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.; Ciciliani A., Wachtel H., Heussel C., Langguth P. Evaluation of Respimat Soft Mist inhaler based on in vitro measurements and CFD simulations. Respir. Drug Delivery. 2015; 2: 357–362.; van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29.; https://journal.pulmonology.ru/pulm/article/view/727Test

الإتاحة: https://doi.org/10.18093/0869-0189-2016-26-3-352-356Test
https://doi.org/10.18093/0869-0189-2016-26-3Test
https://journal.pulmonology.ru/pulm/article/view/727Test

المؤلفون: АВДЕЕВ С.Н., ТРУШЕНКО Н.В.

مصطلحات موضوعية: ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ,АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ,β2-АГОНИСТЫ,КОМБИНАЦИЯ,ОЛОДАТЕРОЛ,ТИОТРОПИЯ БРОМИД,РЕСПИМАТ

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/dvoynaya-bronhodilatatsiya-novaya-paradigma-dlitelnoy-terapii-hronicheskoy-obstruktivnoy-bolezni-legkihTest
http://cyberleninka.ru/article_covers/16435735.pngTest

المؤلفون: Прозорова, Валерия, Абросимов, Анатолий, Архипов, Владимир

مصطلحات موضوعية: ДОЗИРОВАННЫЕ АЭРОЗОЛЬНЫЕ ИНГАЛЯТОРЫ,ПОРОШКОВЫЕ ИНГАЛЯТОРЫ,РЕСПИМАТ

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/sredstva-dostavki-preparatov-v-pulmonologiiTest
http://cyberleninka.ru/article_covers/15734012.pngTest

المؤلفون: Архипов, Владимир

مصطلحات موضوعية: БРОНХИАЛЬНАЯ АСТМА,НЕКОНТРОЛИРУЕМОЕ ТЕЧЕНИЕ,ТИОТРОПИЯ БРОМИД,РЕСПИМАТ

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/novye-perspektivy-povysheniya-kontrolya-nad-bronhialnoy-astmoy-ot-nauki-k-praktikeTest
http://cyberleninka.ru/article_covers/15576889.pngTest

المصدر: Практическая пульмонология.

مصطلحات موضوعية: ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ,АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ,β2-АГОНИСТЫ,КОМБИНАЦИЯ,ОЛОДАТЕРОЛ,ТИОТРОПИЯ БРОМИД,РЕСПИМАТ

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2806::f693b1f8d096203d09bddd8df78d718dTest
http://cyberleninka.ru/article_covers/16435735.pngTest

المصدر: Практическая пульмонология.

مصطلحات موضوعية: БРОНХИАЛЬНАЯ АСТМА,НЕКОНТРОЛИРУЕМОЕ ТЕЧЕНИЕ,ТИОТРОПИЯ БРОМИД,РЕСПИМАТ

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2806::6e18636281698d7c9c584639382ab19fTest
http://cyberleninka.ru/article_covers/15576889.pngTest